Cancer Biomarkers Market Size Emerging Trends, New Growth Opportunities Status 2024-2032

Cancer Biomarkers Market Valuation – 2024-2031

The increased emphasis on customized medicine and precision oncology is driving up demand for biomarker-based diagnostics and targeted medicines. Cancer is a primary cause of morbidity and mortality worldwide, thus there is an urgent need for more effective and customized diagnostic techniques and therapies. Biomarkers provide a promising answer by providing information about the molecular signatures associated with cancer genesis, progression, and response to treatment is globally expansion to surpass revenue of USD 19.07 Billion in 2024 and reach USD 55.17 Billion by 2031.

Furthermore, with the developments in genomics, proteomics, and other omics technologies, there is a deeper understanding of the molecular pathways that drive cancer genesis and progression. This knowledge drives the development and validation of new biomarkers capable of reliably detecting cancer at an early stage, predicting therapy response, and monitoring disease progression. The cancer biomarkers market is expected to rise steadily in the coming years to grow at a CAGR of about 14.20 % from 2024 to 2031.

Cancer Biomarkers Market: Definition/ Overview

Cancer biomarkers are molecular indicators found in physiological fluids or tissues that have important diagnostic, prognostic, and predictive roles in cancer detection and treatment. These biomarkers, which include DNA, RNA, proteins, and metabolites, serve critical roles throughout the cancer life cycle, from early detection to treatment selection and disease progression monitoring. Applications span from well-known markers like PSA for prostate cancer screening to new ones like circulating tumor DNA for minimal residual disease monitoring. The future of cancer biomarkers seems optimistic owing to advances in omics technologies, artificial intelligence, and precision medicine. Innovations such as liquid biopsy techniques and multiplex biomarker panels have the potential to improve detection sensitivity and treatment efficacy, paving the way for more precise and customized cancer therapy. As research progresses, cancer biomarkers are set to transform cancer diagnosis, therapy, and patient outcomes in the coming years.

What’s inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Increase Cases of Cancer Improved Diagnostic and Treatment Escalating the Cancer Biomarkers Market?

The increasing number of cancer cases, together with advances in diagnostic and therapeutic modalities, are expected to fuel significant growth in the cancer biomarkers market. As cancer rates rise worldwide due to factors such as aging populations and lifestyle changes, there is a rising need to improve early diagnosis and treatment efficacy. Improved diagnostic tools, such as next-generation sequencing and liquid biopsy, allow for more precise detection of biomarkers, aiding early diagnosis and tailored treatment.

Furthermore, biomarkers are essential instruments for therapeutic monitoring, assisting doctors in determining treatment response and illness progression. Pharmaceutical companies are expanding their investment in biomarker research to create tailored medicines and companion diagnostics, as regulatory support and reimbursement rules favor biomarker-driven diagnostics.

Biomarkers are critical in drug development and clinical trials, allowing for patient stratification, target identification, and therapy response assessment. As pharmaceutical companies embrace biomarker-driven techniques, novel targeted medicines and companion diagnostics emerge, fueling market growth. This trend accelerates innovation, improves treatment efficacy, and promotes customized care, ultimately leading to better patient outcomes in the fight against cancer and other diseases.

For instance, in April 2024, New SPECT/CT technology demonstrated remarkable biomarker detection and provided improved access for prostate cancer patients. The acquisition method reliably detects radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, paving the way for more tailored treatment. The novel imaging approach, which uses lead-212 (212Pb), has the potential to transform practice and enhance access for patients all across the world. The Journal of Nuclear Medicine published the first-in-human images obtained using this technology.

Regulatory support and attractive reimbursement policies for cancer biomarkers help drive market expansion by rewarding investment in R&D activities. Streamlined approval processes and recommendations from regulatory authorities around the world help to accelerate biomarker development and validation, allowing them to be used in clinical practice. Furthermore, favorable reimbursement policies for biomarker-based tests encourage pharmaceutical companies and diagnostic manufacturers to invest in innovative technologies, resulting in increased market opportunities and improved patient access to advanced diagnostic tools, ultimately driving market growth and improving patient care.

Collaborations between academia, industry, and government agencies foster market growth by hastening biomarker discovery and translation into clinical practice. Stakeholders work together through public-private partnerships, consortia, and research networks to share data, standardize protocols, and pool resources, promoting biomarker development innovation. This collaborative approach broadens the repertoire of clinically validated biomarkers, addressing unmet clinical needs and driving market expansion by encouraging the use of advanced diagnostic tools and personalized medicine strategies, ultimately improving patient outcomes in the fight against cancer and other diseases.

Will Lack of Reimbursement Policies for Biomarker Tests Hinder the Growth of the Cancer Biomarkers Market?

The lack of reimbursement rules for biomarker tests may hamper the growth of the cancer biomarkers market. Reimbursement policies play an important role in encouraging investment in research and development by ensuring a financial return on investment. Without good reimbursement, pharmaceutical companies and diagnostic manufacturers may be hesitant to invest in breakthrough biomarker technologies, reducing the availability and accessibility of modern diagnostic tools for cancer screening and treatment monitoring.

Furthermore, a lack of reimbursement may discourage healthcare providers from using biomarker-based tests due to worries about cost-effectiveness and financial viability. This may slow the acceptance of personalized medicine approaches and impede the incorporation of biomarkers into ordinary clinical practice. Furthermore, without financing, patients may encounter financial challenges to obtaining biomarker testing, thereby delaying diagnosis and treatment beginning.

Validation and standardization problems constitute substantial barriers to the expansion of the cancer biomarkers market. Inconsistent techniques, inconsistency in sample processing, and a lack of standardized protocols all impede the reliable and reproducible assessment of biomarkers, limiting their clinical utility and acceptance. Without strong validation and standardization processes, healthcare practitioners may be hesitant to incorporate biomarker-based testing into routine clinical practice, limiting market adoption and hampering progress in personalized medicine for cancer diagnosis, prognosis, and therapy monitoring. Addressing these issues is critical for establishing biomarkers’ credibility and effectiveness, generating market expansion, and improving patient outcomes in the battle against cancer.

The cancer biomarkers industry presents substantial ethical and legal difficulties, including patient privacy, informed permission, and the possible exploitation of genetic data. Clear rules are required to traverse regulatory channels, get consent, and ensure data security, resulting in increased growth and better patient care.

Category-Wise Acumens

Will Rising Prevalence of  Breast Cancer Drive the Cancer Biomarkers Market?

The increasing incidence of breast cancer is expected to cause significant growth in the cancer biomarkers market. Breast cancer is one of the most frequent malignancies worldwide, with rising incidence rates due to variables such as aging populations, lifestyle changes, and improved diagnosis tools.

Biomarkers play an important role in breast cancer management because they enable early detection, precise diagnosis, prognosis prediction, and treatment selection. Biomarker-based tests, such as those for hormone receptors (e.g., estrogen receptor, progesterone receptor) and human epidermal growth factor receptor 2 (HER2), assist clinicians in choosing the best treatment approach, which may include hormone therapy, targeted therapy, or chemotherapy.

Furthermore, new biomarkers such as circulating tumor DNA (ctDNA) and microRNAs show promise in enhancing early detection, monitoring therapy response, and predicting disease recurrence in breast cancer patients. With an increasing emphasis on personalized medicine and precision oncology, the need for biomarker-driven diagnostic and therapeutic techniques is predicted to rise, allowing the cancer biomarkers market to develop significantly in response to the rising prevalence of breast cancer.

For instance, in  June 2023, Breast Cancer Canada, a national charity dedicated to saving lives through breast cancer research, has announced a new research grant in partnership with AstraZeneca Canada, a worldwide, science-driven biopharmaceutical business, and Illumina, a global leader in DNA sequencing and array-based technology. Breast Cancer Canada has recently announced the recipients of its annual Precision Oncology Research Grants.

In April 2024, Lunit’s AI-powered HER2 analyzer, Lunit SCOPE HER2, demonstrated precision in its analysis of 194,259 pan-cancer samples, linking various ERBB2 mutations with changes in HER2 protein expression. This AI-powered examination effectively revealed critical mutation-expression correlations, with an emphasis on exon 20 insertions (ex20ins) and S310x mutations in a variety of malignancies such as NSCLC, urothelial, and breast cancer.

Lung cancer is the fastest-growing category in the cancer biomarkers market, owing to its high incidence rates and urgent clinical need for new diagnosis and treatment approaches. Biomarkers such as genetic alterations (e.g., EGFR, ALK, ROS1), protein markers (e.g., PD-L1), and circulating tumor cells (CTCs) are critical in guiding therapy decisions, predicting prognosis, and monitoring treatment response in lung cancer patients. The expanding use of biomarker-driven techniques, together with advances in genetic profiling and liquid biopsy technology, emphasizes the importance of biomarkers in strengthening personalized treatment and improving patient outcomes in lung cancer management.

Will Increasing Demand for Genetic Biomarkers Boost the Cancer Biomarkers Market?

The increasing demand for genetic biomarkers is likely to boost the cancer biomarkers market. Genetic biomarkers are specific DNA sequences that are associated with a particular disease or condition. In the case of cancer, genetic biomarkers can help identify individuals who are at a higher risk of developing the disease or who may benefit from specific treatments.

As the field of personalized medicine continues to grow, the demand for genetic biomarkers is likely to increase. This, in turn, is likely to drive the growth of the cancer biomarkers market. Biomarkers are an essential tool in the diagnosis, prognosis, and treatment of cancer. They can help identify the disease at an early stage, monitor disease progression, and predict response to treatment.

In addition to genetic biomarkers, other types of biomarkers are also being developed for cancer diagnosis and treatment. These include protein biomarkers, imaging biomarkers, and circulating tumor cells. The development of new biomarkers is likely to further boost the growth of the cancer biomarkers market.

As precision oncology gains pace, driven by a better knowledge of cancer genetics and the development of tailored medicines, demand for genetic biomarkers is predicted to skyrocket, propelling market growth in the cancer biomarkers sector. Furthermore, the use of genetic biomarkers in clinical practice is expected to grow as regulatory bodies and healthcare systems realize their clinical relevance and value in oncology care.

For instance, in December 2023, broadening access to biomarker testing to accelerated precision oncology. Decision oncology Developing single gene tests concurrently with medication development allows researchers to identify and enroll patients eligible for targeted medicines in clinical trials considerably earlier.

Protein biomarkers are the fastest-growing sector in the cancer biomarker market, owing to their critical significance in oncology research and clinical practice. Proteins play an important role in cancer biology, acting as indications of disease existence, progression, and therapy response. Advanced proteomic technologies, such as mass spectrometry and immunoassays, have enabled the identification and confirmation of highly specific and sensitive protein biomarkers.

These biomarkers have the benefit of being easily accessible in physiological fluids such as blood and urine, making them excellent for minimally invasive diagnostic and prognostic studies. Furthermore, the introduction of targeted treatments and immunotherapies has increased demand for protein biomarkers for patient stratification and treatment efficacy monitoring, driving market expansion in this sector.

Gain Access into Cancer Biomarkers Market Report Methodology

Country/Region-wise

Will Increase Adoption of Next-Generation Sequencing Technology in North America Fueling the Cancer Biomarkers Market?

The increasing adoption of next-generation sequencing (NGS) technology in North America is expected to accelerate the growth of the cancer biomarkers market. NGS technology allows for the rapid and cost-effective sequencing of large amounts of DNA and RNA, enabling the identification of new biomarkers and the development of personalized cancer therapies. North America is a major market for NGS technology, with a large number of NGS service providers, academic research centers, and pharmaceutical companies using this technology for biomarker discovery and validation.

Moreover, the North American market is characterized by favorable regulatory policies and reimbursement frameworks for biomarker-based diagnostics and therapies, which further support the growth of the cancer biomarkers market. The US FDA has approved several biomarker-based tests, such as the Oncotype DX test for breast cancer and the FoundationOne test for solid tumors, which have demonstrated improved patient outcomes and reduced healthcare costs.

In addition, the presence of a large number of cancer patients in North America, coupled with the increasing demand for personalized cancer care, is driving the adoption of biomarker-based diagnostics and therapies. According to the American Cancer Society, there were an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the US in 2020. This highlights the urgent need for more effective and customized diagnostic techniques and therapies.

For April 2024, At AACR 2024 Genialis applies machine learning to personalize cancer treatment outcomes.  Genialis revealed how machine learning and RNA-sequencing may find biomarkers to predict and stratify the clinical effect of KRAS inhibition in a real-world cohort of NSCLC patients.

North America’s advanced healthcare infrastructure is a key driver of cancer biomarker market growth. The region’s advanced medical facilities, cutting-edge diagnostic technology, and strong research institutions make it an ideal location for biomarker development, validation, and clinical application. Advanced infrastructure enables the development of novel biomarker-based testing, resulting in earlier cancer identification, tailored therapy choices, and better patient outcomes. Furthermore, the presence of specialist oncology centers and complete cancer care facilities makes it easier to integrate biomarkers into ordinary clinical practice, which drives market expansion and fosters advances in precision oncology.

Will the Increasing Healthcare Spending in Asia Pacific Drive the Cancer Biomarkers Market?

The rising healthcare spending in Asia-Pacific is predicted to considerably fuel the growth of the cancer biomarkers market. As the Asia-Pacific region’s economies grow and develop, healthcare spending rises to meet the growing healthcare demands of its people. This increased investment in healthcare infrastructure, research, and technology provides potential for the creation, acceptance, and use of new diagnostic technologies, such as cancer biomarkers.

The availability of financial resources enables healthcare systems to invest in cutting-edge diagnostic technologies and facilities, simplifying the implementation of biomarker-based testing for cancer detection, diagnosis, and monitoring. Healthcare practitioners can purchase and apply cutting-edge biomarker tests and platforms, allowing them to more reliably identify and stratify cancer patients based on biomarker profiles.

Increased healthcare spending allows providers to improve access to cancer screening and early detection programs, which are critical to improving cancer outcomes. Biomarker-based tests provide the advantage of cancer identification at an early stage, allowing for timely intervention and treatment. As healthcare spending rises, there is more ability to establish population-based screening programs and provide biomarker-driven diagnostic tests to detect cancer at an earlier stage, ultimately improving patient outcomes and boosting demand for cancer biomarkers.

Furthermore, increased healthcare spending encourages investment in research and development activities focused on biomarker identification and validation. This includes financing for collaborative research initiatives, clinical trials, and biomarker validation studies, which are critical for turning biomarker discoveries into clinically relevant tests. Increased financing allows researchers and industry players to accelerate the creation and validation of new cancer biomarkers, broadening the range of biomarker-based diagnostics available for clinical use.

Competitive Landscape

The landscape of cancer biomarkers is characterized by a diverse array of emerging technologies and approaches aimed at improving early detection, diagnosis, prognosis, and treatment monitoring of various cancer types. This includes advancements in genomics, proteomics, metabolomics, and liquid biopsy techniques, which enable the identification and analysis of molecular signatures associated with cancer development and progression. Moreover, novel methodologies such as circulating tumor DNA (ctDNA) analysis, microRNA profiling, and imaging modalities like positron emission tomography-computed tomography (PET-CT) are revolutionizing biomarker discovery and clinical applications. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms enhances the interpretation of complex biomarker data, facilitating personalized medicine strategies. Furthermore, collaborative efforts between academia, industry, and regulatory bodies foster innovation and expedite the translation of promising biomarker candidates into clinical practice, ultimately driving advancements in cancer diagnosis and treatment.

Some of the prominent players operating in the cancer biomarkers market include:

• Abbott Laboratories
• Thermo Fisher Scientific
• Biomérieux SA
• Illumina
• Bio-Rad Laboratories
• Roche Diagnostics
• Qiagen N.V.
• Merck & Co.
• GE Healthcare
• Agilent Technologies.

Latest Developments

• In January 2024, A novel blood test could be used to detect 18 different types of cancer at an early stage, according to a recent study published in the journal BMJ Oncology. The researchers developed the test with the proteomeTrusted Source in mind, which is the entire collection of proteins in the body. According to research led by Dr. Ashkan Afshin, an affiliate associate professor of health metrics sciences at the University of Washington’s Institute for Health Metrics and Evaluation, the gender-specific liquid biopsy test trusted Source, which analyzes the presence of protein biomarkers for various types of cancer in the bloodstream, was able to successfully detect stage 1 cancers 93% of the time in men and 84% of the time in women.
• In February 2022, OncoDNA launched the OncoDEEP Solid Tumor Biomarker Test Kit. The OncoDEEP package, which comprises Twist Bioscience’s enrichment and library preparation solutions, provides labs with a full and dependable option for undertaking thorough NGS analysis of tumor samples.
• In June 2022, Nonagen Bioscience has obtained CE marking for their Oncuria immunoassay for bladder cancer. Oncuria is the first multiplex urine test to quantitatively detect ten biomarkers in urine that are related with bladder cancer.

Report Scope